公开(公告)号：US20230130564A1

公开(公告)日：2023-04-27

申请号：US17823091

申请日：2022-08-30

申请人： CRISPR THERAPEUTICS AG

发明人： Valentin SLUCH ,  Alireza REZANIA ,  Jason SAGERT

IPC分类号： C07K14/74 ,  A61K35/17 ,  C07K14/54 ,  C07K14/725 ,  C07K14/715 ,  C07K14/81 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/90 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/10 ,  C12N15/66

摘要： The present invention relates to, inter alia, an engineered cell (e.g., iPSC, IPS-derived NK, or NK cell) comprising a disrupted B2M gene and an inserted polynucleotide encoding one or more of SERPINB9, a fusion of IL15 and IL15Rα, and/or HLA-E. The engineered cell can further comprise a disrupted CIITA gene and an inserted polynucleotide encoding a CAR, wherein the CAR can be an anti-BCMA CAR or an anti-CD30 CAR. The engineered cell may further comprise a disrupted ADAM17 gene, a disrupted FAS gene, a disrupted CISH gene, and/or a disrupted REGNASE-1 gene. Methods for producing the engineered cells are also provided, and therapeutic uses of the engineered cells are also described. Guide RNA sequences targeting described target sequences are also described.

公开(公告)号：US20230127586A1

公开(公告)日：2023-04-27

申请号：US17933369

申请日：2022-09-19

申请人： CRISPR THERAPEUTICS AG

发明人： Alireza Rezania ,  Valentin Sluch

IPC分类号： C12N5/071 ,  A61P1/18 ,  A61K35/39 ,  C07K14/475 ,  C07K14/525 ,  C07K14/705 ,  C07K14/74 ,  A61K35/545 ,  C12N5/0735 ,  C12N5/074 ,  C12N9/22 ,  C12N15/85 ,  C12N15/90

摘要： Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.

公开(公告)号：US20230126784A1

公开(公告)日：2023-04-27

申请号：US17905325

申请日：2021-03-08

申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE

发明人： Harris GOLDSTEIN ,  Steven C ALMO ,  Scott GARFORTH ,  Mengyan LI

IPC分类号： A61K35/17 ,  C12N15/86 ,  C07K14/74 ,  C07K14/725 ,  C07K14/005 ,  C07K16/28 ,  A61P35/00 ,  A61P35/02 ,  C12N5/0783

摘要： The present disclosure relates to a method of modulating one or more genetically modified cells, e.g., chimeric antigen receptor (CAR)-expressing cells, ex vivo and/or in vivo.

公开(公告)号：US11634773B2

公开(公告)日：2023-04-25

申请号：US16628067

申请日：2018-07-13

申请人： THE FRANCIS CRICK INSTITUTE LIMITED ,  UNIVERSITY COLLEGE LONDON ,  CANCER RESEARCH TECHNOLOGY LIMITED

发明人： Charles Swanton ,  Nicholas McGranahan ,  Rachel Rosenthal

IPC分类号： C12Q1/6881 ,  C12Q1/6869 ,  A61K39/00 ,  C12Q1/6886 ,  C07K14/74 ,  C07K16/28

摘要： The present invention relates to a method for determining whether an HLA allele is lost in a tumour in a subject, wherein said method comprises the step of determining the specific copy number of said HLA allele in said tumour. The invention also relates to a method for treating cancer in a subject, comprising targeting a neoantigen which is predicted to be presented by an HLA molecule encoded by an HLA allele which has been determined not to have been lost in a tumour in said subject.

公开(公告)号：US20230094553A1

公开(公告)日：2023-03-30

申请号：US17822653

申请日：2022-08-26

申请人： Immatics Biotechnologies GmbH

发明人： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC分类号： C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230089882A1

公开(公告)日：2023-03-23

申请号：US17851417

申请日：2022-06-28

申请人： Immatics Biotechnologies GmbH

发明人： Sabrina KUTTRUFF-COQUI ,  Toni WEINSCHENK ,  Jens FRITSCHE ,  Steffen WALTER ,  Norbert HILF ,  Oliver SCHOOR ,  Colette SONG ,  Harpreet SINGH

IPC分类号： A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  C07K16/28 ,  C12Q1/6886

摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US20230088740A1

公开(公告)日：2023-03-23

申请号：US18051268

申请日：2022-10-31

申请人： Immatics Biotechnologies GmbH

发明人： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC分类号： C07K14/74 ,  A61K38/06 ,  C12N9/64 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/00 ,  C07K7/06 ,  C07K7/02 ,  G01N33/50 ,  G01N33/566 ,  C07K16/18 ,  A61K38/08 ,  C07K14/725 ,  G01N33/569 ,  A61K38/17 ,  C12Q1/6886 ,  A01N37/46

摘要： A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20230077903A1

公开(公告)日：2023-03-16

申请号：US18054737

申请日：2022-11-11

申请人： Immatics Biotechnologies GmbH

发明人： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC分类号： C07K14/74 ,  A61K38/06 ,  C12N9/64 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/00 ,  C07K7/06 ,  C07K7/02 ,  G01N33/50 ,  G01N33/566 ,  C07K16/18 ,  A61K38/08 ,  C07K14/725 ,  G01N33/569 ,  A61K38/17 ,  C12Q1/6886 ,  A01N37/46

摘要： A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US11590213B2

公开(公告)日：2023-02-28

申请号：US16719814

申请日：2019-12-18

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Harvey Cantor ,  Hye-Jung Kim ,  Jianmei Wu Leavenworth

IPC分类号： A61K39/00 ,  A61K35/17 ,  C07K14/47 ,  C07K14/74 ,  C12N5/0783

摘要： Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.

公开(公告)号：US20230049040A1

公开(公告)日：2023-02-16

申请号：US17679128

申请日：2022-02-24

申请人： APPLIED STEMCELL, INC.

发明人： Ruby Yanru TSAI ,  Alfonso FARRUGGIO ,  Xiuling CHI ,  Kai WANG

IPC分类号： A61K35/17 ,  C07K14/74 ,  C12N5/0735 ,  C07K14/705 ,  C07K16/28 ,  G01N33/50

摘要： The present disclosure provides compositions and methods for cell transplantation therapy based on forced expression of an exogenous HLA-F protein in donor cells to be transplanted into a subject. In some embodiments, the donor cells express an exogenous chimeric HLA-F protein comprising an extracellular region comprising an HLA-F alpha 1 domain, an HLA alpha 2 domain, an HLA-F alpha 3 domain, a linker and a β2m protein.